Skip to main content
. Author manuscript; available in PMC: 2023 Jan 25.
Published in final edited form as: Circulation. 2022 Jan 5;145(4):242–255. doi: 10.1161/CIRCULATIONAHA.121.056355

Figure 4.

Figure 4.

Hazard ratios for the primary efficacy (top) and safety (bottom) outcomes plotted over the range of baseline age. Hazard ratio > 1 favors warfarin over DOAC, whereas a hazard ratio < 1 favors DOAC over warfarin.

Footnote: X-axis truncated to include 5th and 95th percentiles.